YMAB Y-mAbs Therapeutics
- 11.600
- -0.250-2.11%
- 11.160
- -0.440-3.79%
Y-mAbs Therapeutics News
Y-mAbs Therapeutics Analyst Ratings
Bank of America Securities Sticks to Its Hold Rating for Y-Mabs Therapeutics (YMAB)
Maintaining Buy Rating on Y-Mabs Therapeutics: A Financial and Clinical Catalyst Outlook
Buy Rating Affirmed for Y-Mabs Therapeutics Amid Strong Danyelza Sales and Promising SADA Radiotherapy Platform
Y-mAbs Therapeutics Analyst Ratings
Y-mAbs Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Eli Lilly & Co (LLY) and 4D Molecular Therapeutics (FDMT)
Y-mAbs Therapeutics Analyst Ratings
Buy Rating Affirmed for Y-Mabs Therapeutics on SADA Technology's Promising Radiotherapy Advancements
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target Is $10
HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $11 Price Target
Y-mAbs Therapeutics Analyst Ratings
DANYELZA Sales Projection and Financial Outlook for Y-Mabs Therapeutics: A Comprehensive Buy Rating Analysis
Analysts' Opinions Are Mixed on These Healthcare Stocks: Silk Road Medical (SILK), Illumina (ILMN) and Y-Mabs Therapeutics (YMAB)
Y-mAbs Therapeutics Analyst Ratings
JPMorgan Adjusts Y-mAbs Therapeutics Price Target to $7 From $8, Maintains Underweight Rating
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Y-Mabs Therapeutics (YMAB)
H.C. Wainwright Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)
Morgan Stanley Maintains Underweight on Y-mAbs Therapeutics, Lowers Price Target to $5
Analysis
Price Target
No Data
